Mihael Polymeropoulos Net Worth

The estimated Net Worth of Mihael Hristos Polymeropoulos is at least $21.6 Million dollars as of 4 March 2024. Mihael Polymeropoulos owns over 55,172 units of Vanda Pharmaceuticals Inc stock worth over $9,208,912 and over the last 18 years he sold VNDA stock worth over $8,143,858. In addition, he makes $4,278,140 as President, Chief Executive Officer, and Director at Vanda Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mihael Polymeropoulos VNDA stock SEC Form 4 insiders trading

Mihael has made over 35 trades of the Vanda Pharmaceuticals Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 55,172 units of VNDA stock worth $231,171 on 4 March 2024.

The largest trade he's ever made was exercising 395,621 units of Vanda Pharmaceuticals Inc stock on 21 May 2015 worth over $130,555. On average, Mihael trades about 42,969 units every 99 days since 2006. As of 4 March 2024 he still owns at least 1,871,730 units of Vanda Pharmaceuticals Inc stock.

You can see the complete history of Mihael Polymeropoulos stock trades at the bottom of the page.

Mihael Polymeropoulos biography

Dr. Mihael H. Polymeropoulos, M.D., is President, Chief Executive Officer, Director of the Company. Prior to joining Vanda, Dr. Polymeropoulos was Vice President and Head of the Pharmacogenetics Department at Novartis AG from 1998 to 2003. Prior to his tenure at Novartis, he served as Chief of the Gene Mapping Section, Laboratory of Genetic Disease Research, National Human Genome Research Institute, from 1992 to 1998. Dr. Polymeropoulos is the co-founder of the Integrated Molecular Analysis of Genome Expression Consortium. Dr. Polymeropoulos holds a degree in Medicine from the University of Patras. Polymeropoulos’ qualifications to sit on the Board include his executive experience at Novartis, his expertise in the fields of psychiatry and pharmacogenetics, his extensive knowledge of central nervous system disorders and his long history with the Company.

What is the salary of Mihael Polymeropoulos?

As the President, Chief Executive Officer, and Director of Vanda Pharmaceuticals Inc, the total compensation of Mihael Polymeropoulos at Vanda Pharmaceuticals Inc is $4,278,140. There are no executives at Vanda Pharmaceuticals Inc getting paid more.

How old is Mihael Polymeropoulos?

Mihael Polymeropoulos is 60, he's been the President, Chief Executive Officer, and Director of Vanda Pharmaceuticals Inc since 2010. There are 5 older and 10 younger executives at Vanda Pharmaceuticals Inc. The oldest executive at Vanda Pharmaceuticals Inc is Richard Dugan, 78, who is the Independent Director.

What's Mihael Polymeropoulos's mailing address?

Mihael's mailing address filed with the SEC is 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON, DC, 20037.

Insiders trading at Vanda Pharmaceuticals Inc

Over the last 19 years, insiders at Vanda Pharmaceuticals Inc have traded over $267,060,716 worth of Vanda Pharmaceuticals Inc stock and bought 5,567,934 units worth $25,606,507 . The most active insiders traders include Kevin Ctang Capital Managem..., Nicole Vitullo, and Jesse I Treu. On average, Vanda Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $546,607. The most recent stock trade was executed by Kevin Patrick Moran on 29 July 2024, trading 2,251 units of VNDA stock currently worth $13,326.

What does Vanda Pharmaceuticals Inc do?

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Complete history of Mihael Polymeropoulos stock trades at Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc executives and stock owners

Vanda Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mihael Polymeropoulos,
  President, Chief Executive Officer, Director
• Timothy Williams,
  Senior Vice President, General Counsel, Secretary
• Gunther Birznieks,
  Senior Vice President - Business Development
• Dr. Mihael H. Polymeropoulos M.D.,
  Founder, Pres, CEO & Chairman of The Board
• Dr. Mihael H. Polymeropoulos,
  Founder, Pres, CEO & Director
• Joakim Wijkstrom,
  Sr. VP & Chief Marketing Officer
• Kevin Patrick Moran,
  Sr. VP, CFO & Treasurer
• Timothy Williams,
  Sr. VP, Gen. Counsel & Sec.
• Phaedra Chrousos,
  Independent Director
• Anne Ward,
  Independent Director
• H. Thomas Watkins,
  Independent Chairman of the Board
• Richard Dugan,
  Independent Director
• Stephen Mitchell,
  Independent Director
• Aranthan Jones,
  Chief Corporate Affairs and Communications Officer
• Joakim Wijkstrom,
  Senior Vice President, Chief Marketing Officer
• Kevin Moran,
  Acting Chief Financial Officer, Vice President, Treasurer
• Elizabeth Van Every,
  Head of Corp. Affairs
• Scott L. Howell,
  Chief People Officer
• Kenneth Bate,
  Director
• Michael F Cola,
  Director
• James E Deerfield Mgmt L.P....,
  
• Paolo Baroldi,
  Chief Medical Officer
• Vincent Milano,
  Director
• Steven A Shallcross,
  Sr. VP, CFO, Treasurer
• Albert W. Gianchetti,
  Sr.VP,Chief Commercial Officer
• Tage Honore,
  
• Richard L. Gulino,
  SVP & General Counsel
• James Patrick Kelly,
  EVP & Chief Financial Officer
• Gian Piero Reverberi,
  SVP & Chief Commercial Officer
• James B Tananbaum,
  Director
• Capital Ii Llccare Capital ...,
  
• Robert J More,
  10% owner
• Nicole Vitullo,
  10% owner
• Management Co Ii Llcprospec...,
  
• Brian H Dovey,
  10% owner
• Deepak Shripad Phadke,
  Vice President Manufacturing
• Ventures Iv Lprho Ventures ...,
  
• James C Blair,
  10% owner
• Inc /De Medimmune,
  10% owner
• Wayne T Hockmeyer,
  Director
• Ventures Iv Lprho Managemen...,
  
• Vi Associates, L.P. Dp,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• Venture Partners Ii Lpprosp...,
  
• Jesse I Treu,
  10% owner
• Sciences Investment Fund Pt...,
  
• Kathleen K Schoemaker,
  10% owner
• Thomas Edward Gibbs,
  SVP, Chief Commercial Officer
• James E Deerfield Mgmt L.P....,
  
• Howard H Pien,
  Director
• Steven K Galson,
  Director
• Robert Repella,
  SVP & Chief Commercial Officer
• Stephanie Rast Irish,
  Sr. VP, Acting CFO/Treasurer
• John Joseph Feeney,
  Acting Chief Medical Officer
• Argeris N Karabelas,
  Chairman of the Board
• Brian K Halak,
  Director
• William D Clark,
  Sr VP, Chief Business Officer
• David Russ Ramsay,
  Director
• Kevin Ctang Capital Managem...,